Oruka Therapeutics (NASDAQ:ORKA) Shares Down 7.8% – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price traded down 7.8% during mid-day trading on Thursday . The company traded as low as $31.75 and last traded at $31.7220. 68,378 shares were traded during mid-day trading, a decline of 83% from the average session volume of 414,029 shares. The stock had previously closed at $34.41.

Wall Street Analyst Weigh In

ORKA has been the subject of a number of research reports. UBS Group began coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price for the company. Piper Sandler assumed coverage on shares of Oruka Therapeutics in a research report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price target on the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Wedbush lifted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $54.50.

Oruka Therapeutics Price Performance

The company has a 50 day moving average of $32.65 and a 200-day moving average of $27.29. The company has a market cap of $1.58 billion, a P/E ratio of -17.21 and a beta of -0.38.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. This trade represents a 17.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 21,000 shares of company stock valued at $663,530. Company insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Financial Enhancement Group LLC bought a new stake in Oruka Therapeutics during the third quarter valued at approximately $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $296,000. B Group Inc. increased its holdings in shares of Oruka Therapeutics by 28.8% in the 2nd quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after buying an additional 16,785 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after buying an additional 354,821 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its position in shares of Oruka Therapeutics by 10.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after buying an additional 58,117 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.